Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables - Net: 2014-2024

Historic Receivables - Net for ImmunityBio (IBRX) over the last 3 years, with Dec 2024 value amounting to $2.4 million.

  • ImmunityBio's Receivables - Net rose 666.85% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.0 million, marking a year-over-year increase of 666.85%. This contributed to the annual value of $2.4 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, ImmunityBio's Receivables - Net is $2.4 million, which was up 81.54% from $1.3 million recorded in FY2022.
  • ImmunityBio's Receivables - Net's 5-year high stood at $2.4 million during FY2024, with a 5-year trough of $1.3 million in FY2022.
  • Over the past 2 years, ImmunityBio's median Receivables - Net value was $1.8 million (recorded in 2022), while the average stood at $1.8 million.